Rashed Rezwan Parag, MS
Research Associate & M. Phil. Student
Mr. Rashed Rezwan Parag received his BSc and MS degree from the Department of Biochemistry and Molecular Biology, University of Chittagong, Bangladesh, and started his research carrier in January 2014 at Laboratory of Eukaryotic Gene Expression and Function, BMB, CU. At EuGEF he is involved in number of projects. Earlier, he focuses on the role of signaling molecules in cancer progression under the supervision of Dr. ASM Noman to identify novel diagnostic, prognostic and therapeutic approaches for cancer patients. Now, he is working at EuGEF Lab to address novel mutational maps of the master regulators in cancer pathogenesis under the supervision of Drs. ASM Noman, MM Hossain, and S Chowdhury. Besides, he is working to explore the role of epigenetic changes in the down-regulation of miRNAs in breast cancer.
Outside the lab, he is interested in reading novels and news of scientific discoveries, watching movies, enjoying the aesthetic beauty of nature, etc. He loves to spend his time in the laboratory to unearth the mystery of biological sciences. He enjoys his leisure time with family and friends.
Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, Azad AK, Rahman ML, Barua D, Sultana A, Shirin A, Ferdous J, Parag RR, et al., Scientific Reports. 2017 May 11;7(1):1796; doi: 10.1038/s41598-017-01268-4; PMID: 28496132
Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer. Noman AS, Parag RR, Rashid MI, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Shirin A, Nayeem J, et al., Therapeutic Advances in Medical Oncology. 2020 Mar 13;12:1758835920911229; doi: 10.1177/1758835920911229; PMID: 32206093
Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, et al., Cell Death & Disease. 2020 Aug 20;11(8):663; doi: 10.1038/s41419-020-02907-x; PMID: 3281477